Compare METC & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | METC | JANX |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | 900 | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 994.6M | 840.4M |
| IPO Year | N/A | 2021 |
| Metric | METC | JANX |
|---|---|---|
| Price | $12.56 | $14.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 13 |
| Target Price | $34.00 | ★ $47.00 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | $19.61 | N/A |
| Revenue Next Year | $11.96 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.75 | $12.12 |
| 52 Week High | $57.80 | $35.34 |
| Indicator | METC | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 35.74 | 55.15 |
| Support Level | N/A | $13.13 |
| Resistance Level | $16.20 | $15.49 |
| Average True Range (ATR) | 0.92 | 0.64 |
| MACD | -0.32 | 0.12 |
| Stochastic Oscillator | 2.49 | 61.30 |
Ramaco Resources Inc is a United States-based company that operates as a pure-play metallurgical coal company with operations in southern West Virginia and southwestern Virginia. Its portfolio includes high-quality metallurgical coal reserves & resources, with a focus on properties such as Elk Creek, Berwind, Knox Creek, and Maben. These properties are strategically located to serve North American blast furnace steel mills and coke plants, as well as international metallurgical coal consumers. Additionally, the company controls mineral deposits in Sheridan, Wyoming, exploring potential opportunities in rare earth elements and coal-to-carbon-based products. The company's two operating segments are Metallurgical Coal segment; and Rare Earths and Critical Minerals.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.